Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 (without DAC) Overview, Dosing & Safety | Peptide Database

CJC-1295 (without DAC) (Modified GRF 1-29) Short-Acting Growth Hormone Releasing Hormone Analog Community Research Join others researching CJC-1295 (without DAC) — share findings, ask questions, and learn from real experiences Synthetic growth hormone releasin

By Recovery & Performance Peptides Editorial Team

CJC-1295 (without DAC) (Modified GRF 1-29)

Short-Acting Growth Hormone Releasing Hormone Analog

Community Research

Join others researching CJC-1295 (without DAC) — share findings, ask questions, and learn from real experiences

Synthetic growth hormone releasing hormone analog with short half-life enabling pulsatile GH secretion patterns resembling natural physiology. Unlike CJC-1295 with DAC, this version preserves natural GH pulsatility without continuous elevation.

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Molecular Data

Tyrosine

Position 1

Alanine

Position 2

Aspartic Acid

Position 3

Position 4

Isoleucine

Position 5

Phenylalanine

Position 6

Threonine

Position 7

Asparagine

Position 8

Serine

Position 9

Position 10

Arginine

Position 11

Lysine

Position 12

Valine

Position 13

Leucine

Position 14

Position 15

Glutamine

Position 16

Position 17

Position 18

Position 19

Position 20

Position 21

Position 22

Position 23

Position 24

Position 25

Position 26

Position 27

Position 28

Position 29

Position 30

Research Indications

Restores natural GH pulsatility patterns in aging individuals.

Elevates IGF-1 through enhanced GH secretion.

Supports pituitary axis without suppression of natural function.

Supports maintenance of lean muscle mass through GH elevation.

Supports bone health through GH-mediated pathways.

Improvements in skin quality through collagen synthesis.

Enhanced recovery from training through GH elevation.

Improved sleep architecture with bedtime dosing.

Dosing Protocols

Subcutaneous injection is the only effective route. Best administered on empty stomach, 30+ minutes away from food.

Anti-Aging/Wellness

100mcg

2x daily (morning and bedtime)

SubQ

Body Composition

100-150mcg

3x daily (morning, post-workout, bedtime)

Maximum GH Release

200mcg

2-3x daily with GHRP

Sleep Enhancement

100-200mcg

Once at bedtime

Reconstitution Instructions

Bacteriostatic water

Insulin syringes (29-31 gauge)

Alcohol swabs

Sterile work surface

1 Clean vial tops with alcohol pad and allow to dry

2 Draw bacteriostatic water slowly

3 Inject water along vial side

4 Gently roll to mix—avoid vigorous shaking

5 Verify solution clarity; cloudiness indicates degradation

6 Label with date and concentration

7 Refrigerate immediately, use within 30 days

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well-tolerated at recommended doses

Temporary facial flushing/warmth (5-10 minutes post-injection)

Stop Signs - Discontinue if:

Persistent joint pain or carpal tunnel symptoms

Significant water retention or edema

Unexplained headaches or vision changes

Extreme fatigue or lethargy

Allergic reaction signs at injection sites

Contraindications

Active cancer (due to growth-promoting effects)

Diabetic retinopathy

Severe kidney disease

Pregnancy or breastfeeding

Quality Checklist

Good Signs

Vendor provides certificates of analysis (>98% purity)

Proper cold-chain shipping with ice packs/refrigeration

Vacuum-sealed vials showing pressure seal integrity

White/off-white lyophilized powder

Warning Signs

Verify expiration dates; lyophilized peptides stable ~2 years if stored properly

Bad Signs

Pre-reconstituted solutions—peptide degrades rapidly

Discolored powder (yellow/brown indicates degradation)

Cloudy solution after reconstitution

Frequently Asked Questions

How many times per day should CJC-1295 (without DAC) be injected?

CJC-1295 without DAC typically requires 2-3 injections daily (morning, post-workout optional, and bedtime) with 100-300mcg per dose to maintain GH elevation. The 30-minute to 2-hour half-life necessitates multiple daily injections, unlike the weekly DAC variant.

What time of day is best to inject CJC-1295 without DAC?

Optimal timing is upon waking on an empty stomach and before bedtime, with an optional post-workout injection. Inject 30+ minutes away from food to maximize GH release. Bedtime dosing is particularly effective as it amplifies natural sleep-associated GH pulses.

Does CJC-1295 without DAC maintain natural GH pulsatility unlike the DAC version?

Yes, the non-DAC version preserves natural pulsatile GH secretion patterns with its 30-minute half-life, whereas DAC provides continuous elevation. This pulsatility is closer to physiology and results in fewer side effects like joint pain compared to continuous DAC stimulation, making it popular for anti-aging protocols.

Can CJC-1295 be stacked with GHRP peptides for better results?

Yes, combining CJC-1295 without DAC with GHRP-6 or GHRP-2 creates a synergistic 'stack' where the GHRH and GHRP work through complementary pathways to amplify GH release significantly beyond either peptide alone. This is the classic approach for maximizing growth hormone stimulation.

References

Identified CJC-1295 as a tetrasubstituted hGRF(1-29) analog that covalently binds albumin. Showed 4-fold increase in GH area under the curve compared to native hGRF(1-29) in rat pituitary cells.

Single injection of CJC-1295 produced dose-dependent 2- to 10-fold increases in GH for 6+ days and 1.5- to 3-fold increases in IGF-I for 9-11 days in healthy adults. Estimated half-life of 5.8-8.1 days.

GH secretion was increased after CJC-1295 with preserved pulsatility. Basal (trough) GH levels were markedly increased (7.5-fold), demonstrating that CJC-1295 maintains natural GH pulse patterns.

Once-daily CJC-1295 maintained normal body composition and growth in GHRH knockout mice, demonstrating efficacy in restoring GH axis function in GH-deficient animal models.

CJC-1295 administration in normal adults activated the GH/IGF-1 axis and produced measurable serum protein profile changes, providing biomarker evidence for sustained GHRH analog activity.

Related Peptides

Complementary GH release via different receptor pathways. Popular combination.

Amplifies GH pulse when combined.

Potent combination maximizing GH through dual pathways.

Different mechanisms; continuous ghrelin versus pulsatile GHRH.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

CJC-1295 Dosage Protocols

Beginner (Mod GRF 1-29, no DAC) 100 mcg per injection 2x daily (morning + before bed) 8-12 weeks, then 4 weeks off Standard (Mod GRF 1-29, no DAC) 100-150 mcg per injection 3x daily (morning, post-workout, before bed) 12-16 weeks, then 4-6 weeks off Advanced (CJC-1295 with DAC) 2 mg per injection Once per week Beginner (Mod GRF 1-29, no DAC): Best combined with 100 mcg Ipamorelin at the same time. Inject on an empty stomach (no food 1 hour before or 30 min after). Use the CJC/Ipa calculator for exact measurements. Standard (Mod GRF 1-29, no DAC): The pre-bed dose is the most important (syncs with natural GH pulse during deep sleep). Stack with 200 mcg Ipamorelin per dose for best results. Advanced (CJC-1295 with DAC): The DAC version provides sustained GH elevation but less pulsatile release. Some advanced users combine 2 mg DAC once weekly with Mod GRF 1-29 + Ipamorelin on training days for both baseline elevation and acute pulses. These are general guidelines for research purposes. Always consult a healthcare professional before use.
02

Question drills

Open a question for its connected answer.

01What If CJC-1295 Elevates My IGF-1 But I See No Joint Improvement?+

This outcome is plausible and aligns with the indirect mechanism: IGF-1 elevation proves the GH axis is responding, but whether that elevation translates to cartilage repair depends on baseline joint pathology, age, inflammatory burden, and mechanical loading. Younger subjects with acute injuries may respond better than older subjects with chronic degenerative disease. The 2014 GH meta-analysis found cartilage effects only in GH-deficient populations. Eugonadal adults with normal baseline GH may not benefit. If IGF-1 rises but symptoms persist, the peptide is working pharmacologically but the joint pathology may require multimodal intervention beyond GH modulation alone.

SOURCE / realpeptides.co ↗
02What If Human Dosing Extrapolated from Animal Studies Produces Suboptimal Results?+

Recalculate based on receptor occupancy or plasma exposure targets, not body weight ratios. CJC-1295 human trials used 60 mcg/kg as the effective dose, which is proportionally lower than the 100–300 mcg/kg range used in rodents when adjusted for metabolic rate and receptor density. If direct weight-based extrapolation underperforms, the issue is typically feedback inhibition (humans have stronger somatostatin tone) or receptor saturation (human GHRH receptor density is lower). Empirical dose-finding in humans is required. Animal doses predict starting points, not final protocols.

SOURCE / realpeptides.co ↗
03What If I'm Not Sure Whether I Hit a Vein?+

Aspirate before every injection by pulling the plunger back slightly after inserting the needle but before depressing it. If blood appears in the syringe, you've entered a vein. Withdraw the needle, discard the syringe (blood contamination), and prepare a fresh dose with a new needle. If no blood appears after 2–3 seconds of aspiration, proceed with injection. This technique is standard for all subcutaneous protocols and eliminates the already-remote possibility of intravenous delivery.

SOURCE / realpeptides.co ↗
04What If I Stop CJC-1295 After Several Months — Will My Natural GH Production Recover?+

Yes. CJC-1295 stimulates rather than replaces endogenous GH, so discontinuation doesn't require a recovery period. Pituitary somatotrophs continue producing GH throughout CJC-1295 administration because the peptide works through receptor agonism, not negative feedback suppression. IGF-1 levels return to baseline within 10–14 days after the final dose as the peptide clears circulation. This is mechanistically distinct from rhGH therapy, where prolonged exogenous GH administration suppresses pituitary GH secretion through negative feedback. Recovery can take 4–8 weeks after discontinuation, during which endogenous GH production gradually resumes.

SOURCE / realpeptides.co ↗
05What If Reconstituted CJC-1295 Sits at Room Temperature for 6 Hours?+

Discard it. The DAC-albumin bond forms in vivo after injection. It doesn't protect the lyophilized peptide or reconstituted solution from degradation. At room temperature (20–25°C), proteolytic enzymes and oxidative stress degrade unbound peptide at roughly 8–12% per hour. After 6 hours, potency drops below 50%, and you're injecting degraded fragments that won't bind albumin correctly. Once reconstituted with bacteriostatic water, store CJC-1295 at 2–8°C and use within 28 days. Temperature excursions above 8°C for more than 2 hours render the vial unreliable.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research review and sources

Reviewed by: PeptideUniv Research Team Updated: March 26, 2026 Human evidence is limited, so this page leans on early clinical signals, mechanistic work, and preclinical findings rather than settled outcome data.

RESEARCH

Published Research Themes on CJC-1295 without DAC

Study contexts: in vitro assays, ex vivo preparations, and animal models reported in the literature. Common endpoints: molecular pathway activation, biomarker changes, tissue-level observations, and assay readouts. Scope: This page summarizes themes without implying outcomes in humans.

POTENTIAL BENEFITS

Benefits

Potential change in GH pulse signaling in research settings (not fully established for outcomes) Potential IGF-1 changes depending on exposure/formulation (not fully established)
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Comparison Table: CJC-1295 Protocols Across Age Brackets

Before selecting a protocol, understanding how age-related physiology changes dosing requirements clarifies why one-size-fits-all approaches consistently underperform in older coh…

Continue reading

Related articles